Market Overview:
Gaucher disease is a rare, inherited lysosomal storage disorder caused by deficiency of the enzyme glucocerebrosidase. This leads to accumulation of fatty substances called glycosylceramides in certain cells and tissues like liver, spleen, lungs and brain. The accumulation causes enlargement of these organs along with complications. The Gaucher disease treatment market mainly comprises enzyme replacement therapies such as Cerezyme, Cerezyme injection and Vpriv and substrate reduction therapy such as Zavesca. These are indicated for symptomatic treatment of non-neurological manifestations of mild to moderate Gaucher disease and reducing hepatosplenomegaly.
Market key trends:
One of the major trends spurring the market growth is robust drug pipeline by various companies for the rare disease. Companies such as Lixte Biotechnology Holdings Inc, JCR Pharmaceuticals Co Ltd, Pharming Group NV and Orphazyme ApS have various drugs in different stages of clinical trials which can potentially provide alternative treatment options to patients. JCR Pharmaceuticals is evaluating JR-951, a small molecule drug that acts as a pharmacological chaperone for the deficient GCase enzyme. Pharming Group is evaluating leniolisib, a small molecule phosphoinositide 3-kinase inhibitor for type 1 Gaucher disease. These alternative treatment options in pipeline are expected to boost the market growth during the forecast period.
Global Gaucher Disease Treatment Market Share Is Estimated To Witness High Growth Owing To Increasing Research & Development And Rising Number Of Pipeline Drugs
The Gaucher Disease Treatment Market is estimated to be valued at US$ 1.54 Bn or Bn in 2022 and is expected to exhibit a CAGR of 2.50% over the forecast period 2022 to 2029, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increasing research & development activities and rising number of drugs in the pipeline are estimated to drive the growth of the Gaucher disease treatment market over the forecast period. For instance, Lixte Biotechnology Holdings Inc, JCR Pharmaceuticals Co Ltd, Pharming Group NV and Orphazyme ApS have various drugs in pipeline for Gaucher disease treatment. This is expected to provide more treatment options and fuel the market growth. Also, rising cases of Gaucher disease worldwide is projected to augment the demand for disease treatment drugs, thereby propelling the market growth.
Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
